RAHWAY - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 NRG-GY018 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with standard of care chemotherapy then continued as a single agent every six weeks for up to 14 cycles for the first-line treatment of patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient (pMMR) or mismatch repair deficient (dMMR).

Results from the trial showed the KEYTRUDA regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients, regardless of mismatch repair status. These late-breaking data are being presented for the first time during a scientific plenary at the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer (abstract #338166) and are also being simultaneously published in the New England Journal of Medicine. The results are being discussed with regulatory authorities worldwide.

In the pMMR cohort of 591 evaluable patients, after a median follow-up of 7.9 months, the KEYTRUDA regimen significantly reduced the risk of disease progression or death by 46% (HR=0.54 [95% CI, 0.41-0.71]; p

(C) 2023 Electronic News Publishing, source ENP Newswire